@article{6a4923db5d694addab6104361f2521d7,
title = "Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation",
abstract = "Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (for example, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplant experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This report provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.",
keywords = "allogeneic, autologous, hematopoietic cell transplantation, late complications, prevention, screening",
author = "Majhail, {N. S.} and Rizzo, {J. D.} and Lee, {S. J.} and M. Aljurf and Y. Atsuta and C. Bonfim and Burns, {L. J.} and N. Chaudhri and S. Davies and S. Okamoto and A. Seber and G. Socie and J. Szer and {Van Lint}, {M. T.} and Wingard, {J. R.} and A. Tichelli",
note = "Funding Information: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Co-operative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute and the National Institute of Allergy and Infectious Diseases; a Grant/ Cooperative Agreement 5U01HL069294 from the National Heart, Lung and Blood Institute and the National Cancer Institute; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Allos Inc.; Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical Inc.; Biovitrum AB; Blood-Center of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children{\textquoteright}s Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai Inc.; Genentech Inc.; Genzyme Corporation; Histogenetics Inc.; HKS Medical Information Systems; Hospira Inc.; Kirin Brewery Co. Ltd; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals Inc.; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics Inc.; Otsuka America Pharmaceutical Inc.; Pall Life Sciences; Pfizer Inc.; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix Inc.; StemCyte Inc.; StemSoft Software Inc.; Sysmex America Inc.; THERAKOS Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma Inc.; and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense or any other agency of the US Government.",
year = "2012",
month = mar,
doi = "10.1038/bmt.2012.5",
language = "English",
volume = "47",
pages = "337--341",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",
}